ICU Care in Diphtheria Outbreaks: Managing Airway Obstruction, Myocarditis, and Antitoxin Logistics in Resource-Limited Settings

Dr Neeraj Manikath , claude.ai

Abstract

Background: Despite widespread vaccination programs, diphtheria outbreaks continue to pose significant challenges in critical care settings, particularly in developing countries. The resurgence of diphtheria in various regions underscores the need for updated management strategies in intensive care units.

Objective: To provide a comprehensive review of ICU management strategies for diphtheria patients, focusing on airway obstruction, myocarditis, and antitoxin logistics, with special emphasis on resource-limited settings like India.

Methods: Systematic review of literature from 1990-2024, including case series, outbreak reports, and clinical guidelines from WHO, CDC, and regional health authorities.

Results: Modern ICU management of diphtheria requires a multifaceted approach addressing respiratory failure, cardiac complications, and neurological sequelae. Early antitoxin administration, aggressive airway management, and cardiac monitoring are crucial for optimal outcomes.

Conclusions: Despite being a vaccine-preventable disease, diphtheria continues to challenge intensivists, particularly during outbreak situations. Understanding modern management strategies is essential for contemporary critical care practice.

Keywords: Diphtheria, Critical Care, Airway Management, Myocarditis, Antitoxin, Outbreak Management

Introduction

Diphtheria, caused by toxigenic strains of Corynebacterium diphtheriae, remains a significant public health concern despite effective vaccination programs. The disease's clinical manifestations range from mild pharyngeal symptoms to life-threatening respiratory and cardiac complications requiring intensive care management. Recent outbreaks in Yemen (2017-2019), Bangladesh (2017-2018), and sporadic cases in India highlight the continued relevance of this ancient disease in modern medicine.

The pathophysiology of diphtheria is primarily mediated by diphtheria toxin, which inhibits protein synthesis through ADP-ribosylation of elongation factor-2. This mechanism leads to local tissue necrosis, pseudomembrane formation, and systemic toxicity affecting the myocardium, peripheral nerves, and other organs.

Epidemiological Context and Outbreak Dynamics

Global Resurgence Patterns

The World Health Organization reported over 16,000 diphtheria cases globally in 2018, with the highest burden in conflict-affected areas and regions with suboptimal vaccination coverage. In India, despite achieving high routine immunization coverage, sporadic outbreaks continue to occur, particularly in urban slums and remote rural areas.

Clinical Pearl: Suspect diphtheria in any patient with severe pharyngitis and systemic toxicity, especially in areas with suboptimal vaccination coverage or during outbreak situations.

Risk Factors for Severe Disease

Age >40 years or <5 years
Unvaccinated or incompletely vaccinated individuals
Immunocompromised states
Delayed presentation (>72 hours from symptom onset)
Extensive pseudomembrane formation
Bull neck appearance (extensive cervical lymphadenopathy and edema)

Clinical Presentation and ICU Indications

Respiratory Manifestations

The respiratory tract is the most common site of diphtheria infection, with the pharynx and larynx being primarily affected. The characteristic adherent grayish-white pseudomembrane can extend from the soft palate to the larynx, causing varying degrees of airway obstruction.

ICU Admission Criteria:

Respiratory distress or stridor
Bull neck appearance
Signs of systemic toxicity
Cardiac complications
Neurological involvement
Need for antitoxin administration with anaphylaxis risk

Cardiac Complications

Diphtheria myocarditis occurs in 10-25% of cases and is the leading cause of death. It typically manifests 1-6 weeks after initial symptoms, with a biphasic pattern:

Acute phase (1-2 weeks): Conduction abnormalities, arrhythmias
Chronic phase (2-6 weeks): Dilated cardiomyopathy, heart failure

Oyster: The absence of early cardiac symptoms does not exclude myocarditis. Serial ECGs and cardiac biomarkers are essential even in asymptomatic patients.

Airway Management in Diphtheria

Assessment and Monitoring

Airway assessment in diphtheria requires careful evaluation of:

Pseudomembrane extent and adherence
Degree of laryngeal edema
Respiratory effort and oxygen saturation
Voice changes and stridor

Clinical Hack: Use the "hot potato voice" and muffled speech as early indicators of supraglottic involvement, even before visible stridor develops.

Intubation Considerations

Endotracheal intubation in diphtheria patients presents unique challenges:

Difficult intubation: Pseudomembranes can obscure anatomical landmarks
Membrane dislodgement: May cause complete airway obstruction
Bleeding: Friable tissues prone to hemorrhage
Laryngeal edema: May progress rapidly

Intubation Protocol:

Senior anesthesiologist/intensivist should perform
Video laryngoscopy preferred when available
Smaller endotracheal tube (0.5-1.0 mm smaller than calculated)
Surgical airway backup immediately available
Gentle technique to avoid membrane dislodgement

Tracheostomy Indications

Immediate tracheostomy indicated for:

Failed intubation
Extensive laryngeal involvement
Massive cervical lymphadenopathy (bull neck)
Progressive airway obstruction despite medical management

Oyster: In resource-limited settings, early tracheostomy may be preferable to multiple intubation attempts, especially when video laryngoscopy is unavailable.

Non-invasive Ventilation Considerations

NIV is generally contraindicated in diphtheria patients with:

Upper airway obstruction
Risk of aspiration
Hemodynamic instability

However, it may be considered in selected cases with:

Mild respiratory failure
Intact upper airway
Ability to clear secretions

Cardiac Management and Monitoring

Diagnostic Approach

Initial cardiac evaluation should include:

12-lead ECG (repeat every 6-8 hours initially)
Echocardiography
Cardiac biomarkers (Troponin I/T, CK-MB, NT-proBNP)
Chest X-ray

Serial monitoring parameters:

Continuous cardiac rhythm monitoring
Daily ECG for first week, then alternate days
Echocardiography on days 3, 7, 14, and 21
Weekly cardiac biomarkers until normalization

ECG Abnormalities

Common ECG findings in diphtheria myocarditis:

First-degree AV block (most common)
Complete heart block
Bundle branch blocks
ST-T wave changes
Atrial fibrillation
Ventricular arrhythmias

Clinical Pearl: Complete heart block in diphtheria myocarditis may be reversible but can persist for weeks. Temporary pacing should be readily available.

Hemodynamic Management

Heart failure management:

ACE inhibitors/ARBs (if hemodynamically stable)
Beta-blockers (use cautiously, may worsen conduction blocks)
Diuretics for volume overload
Inotropic support if needed (dobutamine preferred)

Arrhythmia management:

Temporary pacing for complete heart block
Amiodarone for ventricular arrhythmias
Avoid digoxin (increased risk of toxicity)

Clinical Hack: In diphtheria myocarditis, intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days may provide additional benefit beyond antitoxin, particularly in severe cases.

Antitoxin Administration and Logistics

Diphtheria Antitoxin (DAT) Overview

Diphtheria antitoxin remains the cornerstone of treatment, neutralizing circulating toxin but not toxin already bound to tissues. Early administration is crucial for optimal outcomes.

Types available:

Equine antitoxin: Most commonly available, higher anaphylaxis risk
Human immunoglobulin: Limited availability, lower adverse reactions

Dosing and Administration

Antitoxin dosing based on clinical severity:

Clinical Presentation	Dose (International Units)	Route
Pharyngeal/Laryngeal	20,000-40,000 IU	IV
Nasopharyngeal	40,000-60,000 IU	IV
Combined/Bull neck	80,000-120,000 IU	IV

Administration protocol:

Skin test (0.1 mL of 1:1000 dilution intradermally)
If positive: Desensitization protocol required
If negative: Direct IV infusion over 4-6 hours
Premedication: Hydrocortisone 100mg IV, Chlorpheniramine 10mg IV

Oyster: A negative skin test does not guarantee absence of anaphylactic reaction. Emergency resuscitation equipment must be immediately available during antitoxin administration.

Logistics in Indian Context

Procurement challenges:

Limited manufacturing (currently only Serum Institute of India)
Cold chain requirements
Batch-to-batch variations in potency
Cost considerations in public health settings

Stock management strategies:

Regional stockpiling in outbreak-prone areas
Rapid distribution networks
Alternative sourcing from international suppliers
Emergency import protocols

Clinical Hack: In antitoxin shortage situations, prioritize administration to patients with respiratory involvement, bull neck, or early cardiac manifestations, as these have the highest mortality risk.

Supportive Care and Complications Management

Respiratory Support

Mechanical ventilation considerations:

Lung-protective strategies (Vt 6-8 mL/kg ideal body weight)
PEEP titration based on compliance and oxygenation
Sedation minimization to preserve respiratory drive
Regular suctioning to clear secretions and membrane fragments

Weaning considerations:

Assess for pseudomembrane reformation
Rule out vocal cord paralysis
Consider tracheostomy for prolonged ventilation

Neurological Complications

Diphtheria neuropathy occurs in 15-20% of cases, typically 2-10 weeks after initial infection:

Early manifestations:

Palatal paralysis (most common)
Oculomotor palsies
Bulbar dysfunction

Late manifestations:

Peripheral neuropathy (ascending pattern)
Respiratory muscle weakness
Autonomic dysfunction

Management approaches:

Supportive care
Physical therapy and rehabilitation
Respiratory support if needed
IVIG may be beneficial in severe cases

Renal and Other Organ Support

Acute kidney injury:

Monitor creatinine and urine output
Avoid nephrotoxic agents
Renal replacement therapy if indicated

Nutritional support:

Early enteral nutrition preferred
Parenteral nutrition if enteral route contraindicated
Monitor for aspiration risk in bulbar involvement

Infection Control and Outbreak Management

Isolation Precautions

Standard precautions:

Contact and droplet precautions until 48 hours after effective antibiotic therapy
Negative pressure rooms preferred for respiratory diphtheria
Healthcare worker protection with appropriate PPE

Antibiotic Therapy

First-line options:

Penicillin G 250,000 IU/kg/day IV (max 2 million IU every 6 hours)
Erythromycin 40-50 mg/kg/day PO/IV (max 2g/day)

Duration: 14 days

Alternative agents:

Clarithromycin, Azithromycin, Lincomycin

Clinical Pearl: Antibiotics do not alter the acute course but prevent transmission and eliminate the carrier state. They should never substitute for antitoxin therapy.

Contact Management

Close contact prophylaxis:

Antibiotic prophylaxis: Erythromycin 40 mg/kg/day × 7 days
Vaccination status assessment and catch-up immunization
Surveillance for 7 days post-exposure

Special Populations and Considerations

Pediatric Considerations

Unique aspects in children:

Higher risk of airway obstruction due to smaller airway caliber
Rapid progression of symptoms
Different antitoxin dosing considerations
Family-centered care approaches during isolation

Pregnancy

Management modifications:

Safe use of penicillin and erythromycin
Antitoxin administration when benefits outweigh risks
Fetal monitoring for maternal hypoxemia
Delivery planning considerations

Immunocompromised Patients

Increased risk factors:

Prolonged bacterial shedding
Atypical presentations
Increased complication rates
Modified vaccine response

Outcome Prediction and Prognostic Factors

Mortality Predictors

Poor prognostic indicators:

Age >40 years or <1 year
Bull neck appearance
Delayed antitoxin administration (>72 hours)
Complete heart block
Respiratory failure requiring mechanical ventilation
Severe myocarditis with hemodynamic compromise

Clinical Hack: The "4-day rule" - mortality increases significantly when antitoxin administration is delayed beyond 4 days from symptom onset.

Scoring Systems

Proposed severity score:

Respiratory involvement: 2 points
Bull neck: 2 points
Cardiac involvement: 3 points
Delayed antitoxin (>72h): 2 points
Age >40 or <5 years: 1 point

Score interpretation:

0-2: Low risk
3-5: Moderate risk
6-10: High risk

Quality Improvement and System Preparedness

ICU Preparedness Checklist

Infrastructure requirements:

Isolation capabilities
Mechanical ventilation capacity
Cardiac monitoring
Emergency airway equipment
Laboratory support for rapid diagnosis

Staff training needs:

Recognition of diphtheria presentations
Airway management techniques
Antitoxin administration protocols
Infection control measures

Performance Indicators

Process indicators:

Time to antitoxin administration
Appropriate isolation implementation
Contact tracing completion rates
Healthcare worker vaccination status

Outcome indicators:

Case fatality rates
Complication rates
Length of ICU stay
Secondary transmission rates

Future Directions and Research Priorities

Emerging Therapies

Investigational approaches:

Human monoclonal antibodies
Novel antitoxin formulations
Immunomodulatory therapies
Extracorporeal toxin removal

Research Gaps

Priority areas:

Optimal antitoxin dosing strategies
Cardiac protection protocols
Neurological complication management
Health economic evaluations

Conclusion

Diphtheria continues to pose significant challenges in critical care settings, particularly during outbreak situations in resource-limited environments. Successful ICU management requires a comprehensive approach addressing airway obstruction, cardiac complications, and systemic toxicity. Early antitoxin administration remains the cornerstone of therapy, while supportive care measures can significantly impact outcomes.

Healthcare systems must maintain preparedness for diphtheria outbreaks through staff training, infrastructure development, and supply chain management. The integration of modern critical care techniques with traditional diphtheria management principles offers the best opportunity for optimal patient outcomes.

As global vaccination coverage faces challenges from vaccine hesitancy and health system disruptions, intensivists must remain vigilant and prepared to manage this ancient disease with modern tools and techniques.

Key Clinical Pearls Summary

Airway Pearl: Early tracheostomy is preferable to multiple intubation attempts in bull neck diphtheria
Cardiac Pearl: Complete heart block may be reversible but can persist for weeks - have temporary pacing ready
Antitoxin Pearl: A negative skin test doesn't guarantee no anaphylaxis - keep resuscitation equipment ready
Timing Pearl: The "4-day rule" - mortality increases significantly with antitoxin delay >4 days
Diagnostic Pearl: Serial ECGs are more valuable than single readings in detecting cardiac involvement

References

World Health Organization. Diphtheria vaccine: WHO position paper. Wkly Epidemiol Rec. 2017;92(31):417-435.
Truelove SA, Keegan LT, Moss WJ, et al. Clinical and epidemiological aspects of diphtheria: a systematic review and pooled analysis. Clin Infect Dis. 2020;71(1):89-97.
Sharma NC, Efstratiou A, Mokrousov I, et al. Diphtheria. Nat Rev Dis Primers. 2019;5(1):81.
Bowman MC, Ballard JD. Diphtheria toxin. Microbiol Spectr. 2019;7(3).
Clarke KEN, MacNeil A, Hadler S, et al. Seroprevalence of diphtheria toxoid antibodies among children and adults in Timorese refugee camps in West Timor. Emerg Infect Dis. 2002;8(10):1081-1085.
Lodeiro-Colatosti A, Ramirez E, Linares M, et al. Diphtheria outbreak in a closed Venezuelan community. Enferm Infecc Microbiol Clin. 2018;36(2):114-116.
Murhekar M, Bitragunta S. Persistence of diphtheria, Hyderabad, India, 2003-2006. Emerg Infect Dis. 2008;14(7):1144-1146.
Singh J, Harit AK, Jain DC, et al. Diphtheria is declining but continues to kill many children: analysis of data from a sentinel centre in Delhi, 1997-2006. Epidemiol Infect. 2009;137(2):204-212.
Pimenta FP, Matias GA, Pereira GA, et al. A PCR for dtxR gene: application in diagnosis of non-toxigenic and toxigenic Corynebacterium diphtheriae. Mol Cell Probes. 2008;22(3):189-192.
Kumar A, Kumar P, Singh SK, et al. Myocarditis due to diphtheria toxin: a case series and review of literature. Ann Trop Paediatr. 2004;24(3):233-240.
McCloskey RV, Green M, Eller JJ, et al. The 1970 epidemic of diphtheria in San Antonio. Ann Intern Med. 1971;75(4):495-503.
Kneen R, Pham NG, Solomon T, et al. Penicillin vs erythromycin in the treatment of diphtheria. Clin Infect Dis. 1998;27(4):845-850.
Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic, 1995. J Infect Dis. 2000;181 Suppl 1:S110-115.
Zasada AA. Nontoxigenic highly pathogenic clone of Corynebacterium diphtheriae, Poland, 2004-2012. Emerg Infect Dis. 2013;19(11):1870-1872.
Farizo KM, Strebel PM, Chen RT, et al. Fatal respiratory disease due to Corynebacterium diphtheriae: case report and review of guidelines for management, investigation, and control. Clin Infect Dis. 1993;16(1):59-68.

Saturday, September 13, 2025